Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Arexvy
SHINGRIX herpes zoster vaccine [recombinant, adjuvanted]
If you can prevent shingles suffering, why wouldn't you?
Date of preparation: September 2023 PM-IE-SGX-WCNT-230004
Quick links
More Information
Get more from GSKpro
Get access to exclusive events on the topics that matter to you, free patient resources including patient support materials, demo devices and updates on the latest in HIV/AIDS, respiratory, oncology and Vaccines
References
- Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
- Arexvy, Summary of Product Characteristics (SPC), available at: https://www.medicines.ie/medicines/arexvy-powder-and-suspension-for-suspension-for-injection-35441/spc. Last Accessed: September 2024
- Zejula, Summary of Product Characteristics (SPC), available at: https://www.medicines.ie/medicines/zejula-100-mg-hard-capsules-35060/spc Last Accessed: September 2024
- Shingrix, Summary of Product Characteristics (SPC), available at: https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc Last Accessed: September 2024
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trade marks are owned by or licensed to the GSK group of companies.
PM-IE-NA-WCNT-220010 Date of Preparation: September 2024
